Testing of a Navigation Intervention for Hepatitis C and HIV (LINKHCV)

• ClinicalTrials.gov Identifier: NCT04499651
• Recruitment Status: Terminated
• First Posted: August 5, 2020
• Last Update Posted: February 26, 2021
• Sponsor: University of California, Los Angeles
• Information provided by (Responsible Party): David Goodman-Meza, MD, University of California, Los Angeles

Study Description

Brief Summary:

This study will evaluate the efficacy of navigation for hepatitis C treatment in people living with both HIV and HCV with criminal justice involvement.

Condition or disease	Intervention/treatment	Phase
HIV (Human Immunodeficiency Virus); Hepatitis C	Behavioral: Navigation	Not Applicable

Detailed Description:

Hepatitis C (HCV) is the most common chronic, blood-borne infection in the U.S. and, untreated, can result in liver failure and liver cancer. Despite advances in treatment and remarkable improvements in cure rates, very few persons with chronic HCV infection are receiving this treatment, especially among people who use drugs, who are also disproportionately HIV-infected and incarcerated. Existing efforts to ensure linkage to and retention in medical care following release from incarceration among people living with both HIV and HCV are generally insufficient. Increasing treatment engagement following release from incarceration can drastically reduce HCV and HIV in the blood, which can limit transmission to sexual and injection drug use partners.

The goal of this study is to evaluate the effect of a novel navigation intervention to improve HIV/HCV treatment engagement among HIV/HCV co-infected adults with criminal justice involvement. The investigators hypothesize that the navigation intervention is more effective than the current standard-of-care approaches to link this population of adults to HIV/HCV treatment. All participants, regardless of study arm, will complete one baseline interview around the time of study enrollment. Follow-up interviews are done at 3 months and 8 months following enrollment (if enrolled in the community) or after release from jail (if enrolled in the jail).

Blood samples to analyze the HCV RNA will be collected or requested from participants' clinics both for the baseline assessment and the assessment conducted 12 weeks after completion of the HCV treatment course (if the HCV RNA result cannot be obtained at 12 weeks, it will done at the 8-month follow-up interview). HIV RNA will be collected from the clinics.

In addition to the interviews and the HCV/HIV RNA assessments, participants assigned to the intervention arm will engage in a six- or seven-session navigation intervention. Participants will be in the study for about 12 months but no more than 3 years.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Health Services Research
• Official Title: Adaptation and Testing of a Navigation Intervention for Hepatitis C and HIV Co-infected Persons Leaving LA County Jail
• Actual Study Start Date: July 31, 2020
• Actual Primary Completion Date: February 22, 2021
• Actual Study Completion Date: February 22, 2021

Arms and Interventions

Arm	Intervention/treatment
No Intervention: Control; All people who are living with HIV who are currently in custody in the Los Angeles County Jail are provided with Transitional Case Management and may also receive Whole Person Care related services regardless of participation in this study. Participants recruited from clinics who do not enroll in the study will be offered HIV/HCV care that follows the national HIV/HCV care guidelines, as provided by participating study clinics. Participants recruited from non-medical community agencies who do not enroll in the study and do not have a regular provider will receive a referral list of HIV/HCV care facilities that follow the national HIV/HCV care guidelines.
Active Comparator: Navigation; Participants will be paired with a navigator and will complete the following didactic sessions in one-on-one format: Session 1: Intervention Overview and Basic HIV/HCV Knowledge and Skills Builder; Session 2: Rapport Building; Session 3: Society and Self and the Role of Disclosure; Session 4: Accompaniment 1; Session 5: Goal-Setting, Problem-Solving and a Disclosure Toolkit; Session 6: Accompaniment 2; Session 7: Accompaniment 3 (ONLY if needed); Weekly check-in calls following Session 2 for six months	Behavioral: Navigation; Trained study navigators will provide one-on-one learning sessions and accompaniments to criminal-justice involved people to help link them to HIV/Hepatitis C care

Outcome Measures

Primary Outcome Measures :

1. Undetectable Hepatitis C RNA [ Time Frame: 8 months ]
   Undetectable Hepatitis C RNA
2. Undetectable HIV RNA [ Time Frame: 8 months ]
   HIV RNA <40 copies/ml

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes
• Gender Eligibility Description: All cis-men (assigned "male" at birth) are eligible for the study regardless of current gender identification.
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria (if recruited in jail)

1. Diagnosed HIV+/HCV co-infection;
2. 18 years of age or older;
3. non-cis women;
4. Fluent in speaking English;
5. Have an anticipated sentence of no more than 12 months;
6. Have detectable Hepatitis C viral load
7. Going to live in LA County, Kern County, San Diego County, Riverside County, Ventura County or San Bernardino County

If recruited outside of jail:

1. Diagnosed HIV+/HCV co-infection;
2. 18 years of age or older;
3. non-cis women;
4. Fluent in speaking English;
5. Incarceration history within the last 12 months of enrollment;
6. Have detectable Hepatitis C viral load
7. Going to live in LA County, Kern County, San Diego County, Riverside County, Ventura County or San Bernardino County

Exclusion Criteria:

1. Inability to give informed consent
2. CD4 count<200

Contacts and Locations

Locations

United States, California

UCLA

Los Angeles, California, United States, 90024

Sponsors and Collaborators

University of California, Los Angeles

Investigators

• Principal Investigator: David Goodman-Meza, MD, MAS; University of California, Los Angeles
• Principal Investigator: Debika Bhattacharya, MD, MSc; University of California, Los Angeles

More Information

• Responsible Party: David Goodman-Meza, MD, Principal Investigator, University of California, Los Angeles
• ClinicalTrials.gov Identifier: NCT04499651
• Other Study ID Numbers: ISR-US-18-10586
• First Posted: August 5, 2020
• Last Update Posted: February 26, 2021
• Last Verified: February 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by David Goodman-Meza, MD, University of California, Los Angeles:

HIV; Hepatitis C; Corrections; Engagement-in-care; Navigation; Criminal justice system

Additional relevant MeSH terms:

Hepatitis A; Hepatitis C; Acquired Immunodeficiency Syndrome; HIV Infections; Hepatitis; Liver Diseases; Digestive System Diseases; Hepatitis, Viral, Human; Virus Diseases; Enterovirus Infections; Picornaviridae Infections; RNA Virus Infections; Flaviviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Lentivirus Infections; Retroviridae Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Slow Virus Diseases